Juozas Gordevicius

Juozas Gordevicius

Auto-generated profile, based on publicly available information

Juozas Gordevicius

VUGENE, Vilnius, Lithuania

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Bioinformatics
Verified
Journal Article
Open access
PDF file
IKIeva Kerseviciute
Ieva Kerseviciute
JGJuozas Gordevicius
Juozas Gordevicius
The interpretation of pathway enrichment analysis results is frequently complicated by an overwhelming and redundant list of significantly affected pathways. Here, we present an R package aPEAR (Advanced Pathway Enrichment Analysis Representation) which leverages similarities between the pathway gene sets and represents them as a network of interconnected clusters. Each cluster is assigned a meaningful name that highlights the main biological themes in the experiment. Our approach enables an automated and objective overview of the data without manual and time-consuming parameter tweaking. The package aPEAR is implemented in R, published under the MIT open-source licence. The source code, documentation, and usage instructions are available on https://gitlab.com/vugene/aPEAR as well as on CRAN (https://CRAN.R-project.org/package=aPEAR).

21 October 2022 in Science Advances
Verified
Journal Article
Open access
Jorge Sanz RosJorge Sanz Ros
Jorge Sanz Ros
NRNekane Romero-García
Nekane Romero-García
Cristina Mas-BarguesCristina Mas-Bargues
Cristina Mas-Bargues
DMDaniel Monleon
Daniel Monleon
JGJuozas Gordevicius
Juozas Gordevicius
Consuelo BorrasConsuelo Borras
Consuelo Borras
Aging is associated with an increased risk of frailty, disability, and mortality. Strategies to delay the degenerative changes associated with aging and frailty are particularly interesting. We treated old animals with small extracellular vesicles (sEVs) derived from adipose mesenchymal stem cells (ADSCs) of young animals, and we found an improvement in several parameters usually altered with aging, such as motor coordination, grip strength, fatigue resistance, fur regeneration, and renal function, as well as an important decrease in frailty. ADSC-sEVs induced proregenerative effects and a decrease in oxidative stress, inflammation, and senescence markers in muscle and kidney. Moreover, predicted epigenetic age was lower in tissues of old mice treated with ADSC-sEVs and their metabolome changed to a youth-like pattern. Last, we gained some insight into the microRNAs contained in sEVs that might be responsible for the observed effects. We propose that young sEV treatment can promote healthy aging.

20 June 2022 in Movement Disorders
Verified
Journal Article
Open access
AXAoji Xie
Aoji Xie
EEElizabeth Ensink
Elizabeth Ensink
PLPeipei Li
Peipei Li
JGJuozas Gordevičius
Juozas Gordevičius
LMLee L. Marshall
Lee L. Marshall
FSFilip Scheperjans
Filip Scheperjans
Background: The gut microbiome and its metabolites can impact brain health and are altered in Parkinson's disease (PD) patients. It has been recently demonstrated that PD patients have reduced fecal levels of the potent epigenetic modulator butyrate and its bacterial producers.Objectives: Here, we investigate whether the changes in the gut microbiome and associated metabolites are related to PD symptoms and epigenetic markers in leucocytes and neurons.Methods: Stool, whole blood samples, and clinical data were collected from 55 PD patients and 55 controls. We performed DNA methylation analysis on whole blood samples and analyzed the results in relation to fecal short‐chain fatty acid concentrations and microbiota composition. In another cohort, prefrontal cortex neurons were isolated from control and PD brains. We identified genome‐wide DNA methylation by targeted bisulfite sequencing.Results: We show that lower fecal butyrate and reduced counts of genera Roseburia, Romboutsia, and Prevotella are related to depressive symptoms in PD patients. Genes containing butyrate‐associated methylation sites include PD risk genes and significantly overlap with sites epigenetically altered in PD blood leucocytes, predominantly neutrophils, and in brain neurons, relative to controls. Moreover, butyrate‐associated methylated‐DNA regions in PD overlap with those altered in gastrointestinal (GI), autoimmune, and psychiatric diseases.Conclusions: Decreased levels of bacterially produced butyrate are related to epigenetic changes in leucocytes and neurons from PD patients and to the severity of their depressive symptoms. PD shares common butyrate‐dependent epigenetic changes with certain GI and psychiatric disorders, which could be relevant for their epidemiological relation. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

16 September 2022 in Science Advances
Verified
Journal Article
Open access
ASAnastasia V. Shindyapina
Anastasia V. Shindyapina
YCYongmin Cho
Yongmin Cho
AKAlaattin Kaya
Alaattin Kaya
ATAlexander Tyshkovskiy
Alexander Tyshkovskiy
JCJosé P. Castro
José P. Castro
VGVadim N Gladyshev
Vadim N Gladyshev
Development is tightly connected to aging, but whether pharmacologically targeting development can extend life remains unknown. Here, we subjected genetically diverse UMHET3 mice to rapamycin for the first 45 days of life. The mice grew slower and remained smaller than controls for their entire lives. Their reproductive age was delayed without affecting offspring numbers. The treatment was sufficient to extend the median life span by 10%, with the strongest effect in males, and helped to preserve health as measured by frailty index scores, gait speed, and glucose and insulin tolerance tests. Mechanistically, the liver transcriptome and epigenome of treated mice were younger at the completion of treatment. Analogous to mice, rapamycin exposure during development robustly extended the life span of Daphnia magna and reduced its body size. Overall, the results demonstrate that short-term rapamycin treatment during development is a novel longevity intervention that acts by slowing down development and aging, suggesting that aging may be targeted already early in life.

26 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJuozas Gordevicius
Juozas Gordevicius
PLPeipei Li
Peipei Li
LMLee L. Marshall
Lee L. Marshall
BKBryan A. Killinger
Bryan A. Killinger
SLSean Lang
Sean Lang
VLViviane Labrie
Viviane Labrie
The gastrointestinal tract may be a site of origin for α-synuclein pathology in idiopathic Parkinson’s disease (PD). Disruption of the autophagy-lysosome pathway (ALP) may contribute to α-synuclein aggregation. Here we examined epigenetic alterations in the ALP in the appendix by deep sequencing DNA methylation at 521 ALP genes. We identified aberrant methylation at 928 cytosines affecting 326 ALP genes in the appendix of individuals with PD and widespread hypermethylation that is also seen in the brain of individuals with PD. In mice, we find that DNA methylation changes at ALP genes induced by chronic gut inflammation are greatly exacerbated by α-synuclein pathology. DNA methylation changes at ALP genes induced by synucleinopathy are associated with the ALP abnormalities observed in the appendix of individuals with PD specifically involving lysosomal genes. Our work identifies epigenetic dysregulation of the ALP which may suggest a potential mechanism for accumulation of α-synuclein pathology in idiopathic PD.

25 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
Ray Bahado-SinghRay Bahado-Singh
Ray Bahado-Singh
URUppala Radhakrishna
Uppala Radhakrishna
JGJuozas Gordevičius
Juozas Gordevičius
BABuket Aydas
Buket Aydas
Ali YilmazAli Yilmaz
Ali Yilmaz
Sangeetha VishweswaraiahSangeetha Vishweswaraiah
Sangeetha Vishweswaraiah
Background: Despite extensive efforts, significant gaps remain in our understanding of Alzheimer’s disease (AD) pathophysiology. Novel approaches using circulating cell-free DNA (cfDNA) have the potential to revolutionize our understanding of neurodegenerative disorders. Methods: We performed DNA methylation profiling of cfDNA from AD patients and compared them to cognitively normal controls. Six Artificial Intelligence (AI) platforms were utilized for the diagnosis of AD while enrichment analysis was used to elucidate the pathogenesis of AD. Results: A total of 3684 CpGs were significantly (adj. p-value < 0.05) differentially methylated in AD versus controls. All six AI algorithms achieved high predictive accuracy (AUC = 0.949–0.998) in an independent test group. As an example, Deep Learning (DL) achieved an AUC (95% CI) = 0.99 (0.95–1.0), with 94.5% sensitivity and specificity. Conclusion: We describe numerous epigenetically altered genes which were previously reported to be differentially expressed in the brain of AD sufferers. Genes identified by AI to be the best predictors of AD were either known to be expressed in the brain or have been previously linked to AD. We highlight enrichment in the Calcium signaling pathway, Glutamatergic synapse, Hedgehog signaling pathway, Axon guidance and Olfactory transduction in AD sufferers. To the best of our knowledge, this is the first reported genome-wide DNA methylation study using cfDNA to detect AD.